Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company focused on in-office dermatologic devices, and its news flow reflects that specialization. Company announcements frequently highlight developments related to its core technologies: the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClearX® Acne Therapy System. These updates often cover new clinical evidence, regulatory milestones, reimbursement decisions, and commercial expansion in dermatology markets.
Investors and clinicians following SSKN news can expect regular coverage of peer-reviewed studies involving XTRAC in conditions such as psoriasis, vitiligo, atopic dermatitis, and mycosis fungoides, including combination regimens with topical drugs and JAK inhibitors. STRATA frequently reports on published data that it believes support the safety, efficacy, and personalized use of excimer laser therapy across a range of inflammatory and autoimmune skin diseases.
News items also address reimbursement and policy developments. STRATA has issued releases on CMS Medicare Physician Fee Schedule decisions related to CPT® codes 96920–96922, including continued coverage, payment levels, and recognition of future code descriptor expansions for excimer laser procedures. These updates are relevant for understanding how reimbursement may influence utilization of XTRAC in U.S. dermatology clinics.
Corporate and capital markets updates are another recurring theme. STRATA uses news releases to communicate quarterly financial results, non-GAAP performance metrics, registered direct offerings, and at-the-market equity programs. The company also reports on its legal and competitive positioning, including litigation milestones against competing device manufacturers and the recapture of dermatology clinics into its XTRAC partnership network.
International growth initiatives, such as COFEPRIS clearance for TheraClearX in Mexico and partnerships with commercialization firms like MINO Labs, appear in STRATA’s news as the company expands its device-based acne and phototherapy offerings beyond the United States. For users of this SSKN news page, the feed provides an ongoing view into STRATA’s clinical, regulatory, commercial, and financial developments in the dermatology device space.
STRATA Skin Sciences (NASDAQ: SSKN) plans to announce its Q1 2021 financial results on May 12, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide corporate updates. The call will be webcasted, and details will be available on their website. STRATA specializes in innovative dermatological treatments, including the XTRAC excimer laser and VTRAC lamp systems, which target conditions like psoriasis and vitiligo affecting over 31 million patients in the U.S.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced the appointment of William D. Humphries to its Board of Directors. With over 34 years in the pharmaceutical industry, Humphries aims to bolster STRATA's growth in dermatology. He previously led Ortho Dermatologics and served as CEO of Merz’s North American business. STRATA focuses on innovative dermatologic treatments, including the patented XTRAC excimer laser, benefiting over 31 million patients in the U.S. This leadership change is expected to enhance the company's strategic direction and innovation.
STRATA Skin Sciences (SSKN) reported Q4 2020 revenues of $6.7 million, a 24.5% drop from Q4 2019. Global recurring revenue fell by 22.7% to $5.1 million, though it showed a 32.4% increase from Q3 2020. Gross profit margin was 67.6%, down from 68.8% year-over-year. For the full year, total revenue declined to $23.1 million from $31.6 million in 2019, with a net loss widening to $4.4 million. The company ended the year with $18.1 million in cash and a 30-device increase in its XTRAC device base to 860.
STRATA Skin Sciences, a leader in dermatology tech, announced its participation in the Lytham Partners Spring 2021 Investor Conference on March 30 at 3:30 p.m. ET. The event will include management presentations and virtual one-on-one meetings from March 30 to April 1, 2021. Interested parties can access the presentation via the company's website. STRATA specializes in innovative products for dermatologic conditions, including the XTRAC® excimer laser. With over 832 partner clinics and a global device base exceeding 2,300, STRATA aims to revolutionize skin disease treatment.
STRATA Skin Sciences (NASDAQ: SSKN) announced a study revealing effective vitiligo treatment using its XTRAC excimer laser, achieving satisfactory repigmentation in five sessions. Conducted in Japan, the study published in November 2020 indicates improved results over traditional therapies like UVB light. The XTRAC's higher irradiation rate was highlighted, along with reduced treatment burdens. STRATA aims to address the unmet need in Japan for vitiligo treatment, bolstered by positive clinical outcomes supporting its innovative technology.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced it will release its fourth quarter and full year financial results on March 24, 2021, after market close. Management will hold a conference call at 4:30 p.m. ET to discuss the results and provide a corporate update, which will also be webcasted. STRATA specializes in medical technology, focusing on innovative products for dermatological conditions, including its XTRAC® excimer laser. The company’s DTC advertising strategy has expanded its partner dermatology clinic network to over 832 locations across the U.S.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has expanded its direct distribution agreement with Wuhan Miracle Laser Systems, Inc. to enhance its presence in the Chinese dermatology market. This agreement aims to generate recurring revenues from XTRAC® excimer laser placements and direct sales. With over 180 devices installed, STRATA seeks to leverage its robust business model and strong balance sheet to support growth in China. This partnership builds on a 15-year collaboration with Miracle, a leading medical device distributor in the region.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced the grant of equity-based awards to Robert Moccia, who has commenced his role as CEO and President. Effective March 1, 2021, Moccia received stock options to purchase 1,632,590 shares at a strike price of $1.73, vesting over three years. This decision supports the company's strategic goal to enhance its leadership in dermatology, particularly through its innovative treatment solutions like the XTRAC® excimer laser, which serves millions of patients with various skin conditions.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced the appointment of Robert Moccia as President and CEO, effective March 1, 2021, following the departure of Dolev Rafaeli, Ph.D. Moccia brings over three decades of experience in dermatology, previously founding Encore Dermatology and doubling revenues at Precision Dermatology, leading to a significant acquisition. The company plans to release its Q4 2020 financial results on March 24, 2021, aiming to enhance its position in the growing dermatology market through its innovative products and direct-to-consumer business model.
STRATA Skin Sciences reported preliminary fourth quarter revenues of $6.6 million to $6.8 million, down from $8.9 million in Q4 2019. Recurring revenues are projected between $5.0 million and $5.2 million, compared to $6.6 million a year prior. The company saw a net increase of 19 XTRAC systems placed domestically. Cash and cash equivalents rose to $18.0 million as of December 31, 2020. Despite challenges due to COVID-19, December 2020 marked the highest gross domestic billing month of the year. Final audited results will be released in late March.
FAQ
What is the current stock price of Strata Skin Sciences (SSKN)?
What is the market cap of Strata Skin Sciences (SSKN)?
